Needham & Company Awaits NDA Filing, Reit Buy on Sarepta Therapeutics (SRPT)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Sarepta Therapeutics (SRPT) Misses Q1 EPS by 15c
May 7, 2015 7:47 AM EDTSarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($1.15), $0.15 worse than the analyst estimate of ($1.00).
Sarepta said its pre-NDA meeting with the FDA remains calendared for second quarter 2015.
For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.
... MoreBaird Upgrades Sarepta Therapeutic (SRPT) to Outperform; Favorable Risk/Reward
May 6, 2015 6:10 AM EDTBaird upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Neutral to Outperform with a price target of $20.00 (from $16.00), citing favorable risk/reward into FDA guidance.
Analyst Brian Skorney commented, "We're jumping back into the stock after last week's NDA submission by potential competitor... More
